Acceptability and necessity of HIV and other blood-borne virus testing in a psychiatric setting

Camilla Sanger, Janine Hayward, Gira Patel, Karen Phekoo, Alan J. Poots, Cathy Howe, Owen Bowden-Jones and John Green

Summary

Studies in North America and Europe indicate that the prevalence of blood-borne viruses (BBVs) is elevated in individuals with severe mental illness; there are no comparable data for the UK. We offered routine testing for HIV, and hepatitis B and C in an inner-London in-patient psychiatric unit as a service improvement. Of the patients approached 83% had mental capacity to provide informed consent for testing and 66% of patients offered testing accepted. Although it was not our objective to establish the prevalence of BBVs, 18% of patients had serological evidence of a current or previous BBV infection. We found that offering routine testing in an in-patient psychiatric setting is both practical and acceptable to patients.

Declaration of interest

None.

Method

A total of 105 patients of whom 64% were male aged between 21 and 71 years old from a central London psychiatric hospital (three open admission wards and one intensive care unit) were approached (up to a maximum of three times) and offered BBV tests over a 12-month period. Where patients were identified by staff as very disturbed on a particular day, the offer of a test was delayed and the patient approached later. All participants were provided with an information leaflet and a written account of BBV testing; interpreters were utilised for non-English speakers. Testing was offered by a trained clinical member of the service improvement team who also notified the patient of their results and arranged specialist support for any patient with a positive result. Where possible, tests were undertaken on blood already collected for other tests. Demographic data, psychiatric diagnosis, mental capacity to test, test uptake, test result and transfer to care were collected.

Results

Table 1 shows that 83% (87/105) of the participants had mental capacity to make an informed decision regarding testing. Of those with mental capacity 66% (57/87) gave informed consent. During result notification and follow-up there were no reports by patients or staff of patients being distressed by the offer of a test.

Although this was a service improvement project and not an epidemiological study, prevalence of BBVs in this cohort was high. In total 18% (10/57) of the consenting patients and 13 individuals (12%) in the entire cohort showed serological evidence of past or current infection with a BBV or had a known history of BBVs. Four individuals with current or past infections were identified for the first time including one person dually infected with HIV and hepatitis B. A further nine patients were already known to services.

Discussion

Testing for BBVs in a psychiatric setting was acceptable to the majority of patients with severe and enduring mental illness and feasible to deliver. The strategy was successful in identifying and engaging in appropriate care for previously undiagnosed BBV-infected individuals. However, testing was delivered by staff within the service improvement team and further work needs to be conducted to find ways to integrate BBV testing sustainably into standard clinical procedures.

At the outset there were concerns among some staff about patients’ capacity to provide informed consent and about the possibility that offering tests might be disturbing to patients. In practice it was straightforward to obtain consent. Previous research indicates that the vast majority of individuals with schizophrenia are able to provide informed consent. An educational intervention across more than one session can allow many of those with a reduced capacity to provide informed approval. Capacity in mental health patients varies over time and some in this cohort who lacked capacity initially were able to consent to BBV testing when re-approached at a later date. Similarly, patients welcomed the offer of a test even when deciding to refuse and reacted with appreciation for the service’s interest in their entire well-being rather than appearing distressed.

In conclusion, the routine offering of BBV testing was both acceptable to patients and feasible in this in-patient mental health setting. The project was small and not intended to establish the epidemiology of BBVs among our in-patients and it was carried out in an area where the background population rate of BBVs is high. However, the prevalence in our cohort was strikingly high,
results which are consistent with studies elsewhere suggesting that people with severe mental illness are at increased risk of BBVs. Hepatitis B and C and HIV are treatable conditions; but it is vitally important to diagnose them early. For instance most deaths from HIV occur in those who are detected late, whereas treatment markedly reduces infectiousness and hence, potentially, population spread. There is a strong case for a study to establish the prevalence of BBVs in patients with severe mental illness nationally and for the routine offer of testing to this group nationally, particularly in areas of high-population prevalence. If BBV interventions are to be included as a routine part of patients’ care, additional resources and staff training will be required.

Camilla Sanger, BSc Hons, Janine Hayward, MPhil (Cantab), Department of Clinical Health Psychology, Central and North West London NHS Foundation Trust, London; Gira Patel, MBChB, MRCPsych, Department of General Adult Psychiatry, Central and North West London NHS Foundation Trust, London; Karen Phelkoo, DMS, DipM, Msc Sc, PhD, Alan J. Poole, MA (Oxon) MSc, PhD, FLS, Cathy Howe, BSc, DipPsych, MSc, PGC, Department of Clinical Health Psychology, Central and North West London NHS Foundation Trust, London; John Green, PhD, Department of Clinical Health Psychology, Central and North West London NHS Foundation Trust, London, UK

Acknowledgements

We thank Dr R Taylor, consultant psychiatrist, and Dr A Mears, consultant physician. This paper presents independent research by the National Institute for Health Research (NIHR) under the CLAHRC programme for North West London. The views expressed in this publication are those of the authors and not necessarily those of the NHS, NIHR or the Department of Health.

References


Table 1 Acceptability of testing for blood-borne viruses (BBVs; HIV, hepatitis B and hepatitis C) in psychiatric in-patients

<table>
<thead>
<tr>
<th></th>
<th>Approached (n = 105)</th>
<th>Capacity (n = 87)</th>
<th>Consent gained (n = 57)</th>
<th>Consenting individuals with newly identified BBV</th>
<th>Consenting individuals with known BBV</th>
<th>Non-consenting individuals with known BBV</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>HIV</td>
<td>Hepatitis B</td>
<td>Hepatitis C</td>
<td>HIV</td>
<td>Hepatitis B</td>
<td>Hepatitis C</td>
</tr>
<tr>
<td>Male</td>
<td>67 (64)</td>
<td>56 (64)</td>
<td>41 (72)</td>
<td>1</td>
<td>1</td>
<td>4</td>
</tr>
<tr>
<td>Female</td>
<td>38 (36)</td>
<td>31 (36)</td>
<td>16 (28)</td>
<td>1</td>
<td>1</td>
<td>1</td>
</tr>
</tbody>
</table>

a. One person with dual (HIV-hepatitis B) diagnosis.

Funding

Funding was provided by Central and North West London NHS Foundation Trust and the Collaborations for Leadership and Applied Health Research and Care (CLAHRC) programme for North West London.
Acceptability and necessity of HIV and other blood-borne virus testing in a psychiatric setting
Camilla Sanger, Janine Hayward, Gira Patel, Karen Phekoo, Alan J. Poots, Cathy Howe, Owen Bowden-Jones and John Green
Access the most recent version at DOI: 10.1192/bjp.bp.112.119529

References
This article cites 8 articles, 1 of which you can access for free at:
http://bjp.rcpsych.org/content/202/4/307#BIBL

Reprints/permissions
To obtain reprints or permission to reproduce material from this paper, please write to permissions@rcpsych.ac.uk

You can respond to this article at:
/letters/submit/bjprcpsych;202/4/307

Downloaded from
http://bjp.rcpsych.org/ on April 20, 2017
Published by The Royal College of Psychiatrists